Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 11 -19 of 19 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/10/2007 First Published: 11/22/2004


11.		Phase I Study of Doxorubicin and Flavopiridol in Patients With Unresectable Metastatic or Locally Recurrent Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MSKCC-04075 NCI-6204, 6204, NCT00098579

Last Modified: 12/21/2007 First Published: 11/22/2004


12.		Phase I Study of FR901228 (Depsipeptide) and Flavopiridol in Patients With Advanced Primary Lung or Esophageal Cancer, Malignant Pleural Mesothelioma, or Lung or Pleural Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				NCI-05-C-0010 5987, NCI-5987, NCT00098644

Last Modified: 3/8/2007 First Published: 12/22/2004


13.		Phase I Study of Flavopiridol in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				1 and over				NCI				OSU-2004C0085 6947, NCI-6947, OSU-0479, NCT00101231

Last Modified: 10/29/2007 First Published: 5/23/2005


14.		Phase I Pilot Study of Flavopiridol in Patients With Locally Advanced or Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				OSU-04111 OSU-2005C0009, 7204, NCI-7204, NCT00112684

Last Modified: 5/2/2008 First Published: 1/13/2006


15.		Phase I Study of Flavopiridol and Vorinostat in Patients with Relapsed, Refractory, or Selected Poor Prognosis Acute Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Refractory Anemia With Excess Blasts-2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MCV-MCC-6637 6637, NCI-6637, NCT00278330

Last Modified: 4/10/2007 First Published: 5/5/2006


16.		Phase I Study of Vorinostat (SAHA) in Combination With Flavopiridol in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MSKCC-05109 6858, NCI-6858, NCT00324480

Last Modified: 7/26/2007 First Published: 9/10/2006


17.		Phase I Study of Flavopiridol as Consolidation Chemotherapy After Cytoreduction Chemotherapy in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				OSU-05116 OSU-IRB-2006C0031, 7368, NCI-7368, NCT00377104

Last Modified: 7/12/2007 First Published: 5/1/2007


18.		Phase I Study of a Hybrid Bolus-Infusion Schedule of Flavopiridol Given in Timed Sequential Combination With Cytarabine and Mitoxantrone Hydrochloride in Patients With Relapsed or Refractory Acute Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment				Active				18 and over				NCI				JHOC-7889 7889, NCT00470197

First Published: 8/13/2008


19.		Phase I Study of Lenalidomide and Alvocidib in Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				OSU-08056 08056, 8046, 2008C0033, NCT00735930

Select All on One Page


					< Previous 1 2

| | | | | | | |

A Service of the National Cancer Institute